ArticleFrontiers in public health2025
A twenty-eight-day evaluation of cytotoxic drug vapor containment in drug-binding closed-system transfer device.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Several studies have demonstrated that hazardous drugs can evaporate even at ambient temperature during their preparation in healthcare facilities, potentially posing a health risk for clinicians. The National Institute for Occupational Safety and Health (NIOSH) has defined closed system transfer device (CSTD) performance as preventing the release of hazardous drugs in the form of vapor, aerosol, or droplets. Most CSTDs can be used to store drugs for up to 7 days after their preparation. However, as some drugs are stable for more than 7 days, the CSTD usage period represents a limiting factor leading to residual drug waste. We investigated whether the Chemfort Methods: Cyclophosphamide, a cytotoxic drug with relatively high vapor pressure was chosen as the representative drug to demonstrate vapor escape prevention. Testing was performed using intact vial adaptors (with ToxiGuard Results: No escaped cyclophosphamide was detected in the tests performed using Chemfort Conclusion: The intact ToxiGuard
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.